GDC-0853

Fenebrutinib (GDC-0853) is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK.


Cat. No.: EX-A1308	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	685	In-stock
250mg	900	In-stock
500mg	1450	In-stock
1g	2450	In-stock
5g	6550	In-stock
10g	9550	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Fenebrutinib
CAS No.	1434048-34-6
Purity	>98%
Formula	C37H44N8O4
Mol Weight	664.7965
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Erickson RI , et al. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther. 2017 Jan;360(1):226-238. [2]. Crawford JJ, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018 Mar 22;61(6):2227-2245.
CoA	CoA of GDC-0853

Smiles:	C[C@H]1CN(CCN1C1=CN=C(NC2=CC(=CN(C)C2=O)C2=CC=NC(N3CCN4C(=CC5=C4CC(C)(C)C5)C3=O)=C2CO)C=C1)C1COC1


		Search